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reflect distinct pathways in the development and 
progression of AS.
The inflammation/calcification/ossification 
processes have been extensively monitored by var-
ious biomarkers4 indicating dysregulated mech-
anisms resposible for aortic valve damage. How-
ever, targeted medical therapies capable of mod-
ifying disease progression are not available yet.
AS can be divided into 2 distinct stages: an ear-
ly initiation phase, dominated by valvular lipid 
deposition, injury, and inflammation, and a lat-
er propagation phase, where procalcific and pro-
osteogenic factors take over and ultimately drive 
disease progression.5
The link between lipid, inflammation, and cal-
cification in these early stages and the patholog-
ical similarities with atherosclerosis led to the 
hypothesis that treatment with statins might be 
beneficial in AS patients. This was supported by 
human data (RAAVE study)6 and experimental 
studies in hypercholesterolemic animal models,7 
demonstrating that lipid deposition and oxida-
tive stress precede the conversion of valvular in-
terstitial cells to those with an osteoblastic pheno-
type, and that this process is inhibited by statins. 
However, when statins were prospectively tested 
in randomized controlled trials (SALTIRE,8 AS-
TRONOMER,9 and SEAS10), each demonstrated 
a failure of this therapy to halt or retard AS pro-
gression. This observation has led researches to 
analyze again the pathophysiology of AS under-
lying AS and to the observation that although in-
flammation and lipid deposition may be impor-
tant in provoking or establishing the disease (the 
initiation phase), the later stages are character-
ized instead by a self-perpetuating cycle of calci-
um formation, resulting in valvular injury (the 
propagation phase). Indeed, once this propaga-
tion phase has become established, disease pro-
gression is governed neither by inflammation nor 
by lipid deposition, but rather by the relentless 
Aortic stenosis (AS) is the most common form of 
valve disease in the world and a rapidly increas-
ing public health burden (especially in the elder-
ly). AS occurs in almost 10% of adults over the 
age of 80 years, with a mortality about 50% at 2 
years, unless valvular stenosis is relieved by inter-
vention (aortic valve replacement or transcathe-
ter aortic valve implantation).
In a recent study on AS patients, Lis et al.1 used 
an attractive “double-assessment” methodology. 
Firstly, an indirect assessment was based on the 
measurement of biomarkers in serum before valve 
replacement, and secondly, excised valves were 
evaluated in a pathomorphological examination. 
The preoperative low concentration of osteopro-
tegerin (OPG) in plasma was associated with the 
presence of intravalvular osteoclastic differen-
tiation in a histopathologic analysis in excisied 
valves.1 From the clinical point of view, this ob-
servation is important because plasma OPG lev-
els (in preoperative measurement) are related to 
postoperative outcome.2 Accordingly, patients 
with low OPG levels have a more favorable out-
come in the postoperative follow-up in compar-
ison with patients with high OPG levels, which 
may help identify individuals with poor improve-
ment of symptoms during long-term follow-up 
after aortic valve replacement.2 
In a preoperative echocardiographic examina-
tion, high OPG levels were associated with path-
ological left ventricular and left atrial remodel-
ing.2 In line with the results by Ueland et al,3 high 
OPG levels were associated with all-cause mortal-
ity in patients with symptomatic AS in the anal-
ysis of combined follow-up (including both pa-
tients with and without valve replacement), even 
after adjustment for conventional risk markers. 
The strongest association was obtained by using 
a combination of high levels of both OPG and 
N-terminal pro-B-type natriuretic peptide. The 
authors3 have suggested that these markers may 
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Bisphosphonates and denosumab hold promise 
as novel treatments for AS and are currently being 
investigated in an ongoing randomized controlled 
trial, SALTIRE II.17 The ability of lipoprotein(a)-
-lowering treatment to modify AS progression is 
likely to form the basis of a future clinical trial.
Summarizing, recent insights into the patho-
physiology of AS have documented that although 
lipid and inflammation may be important in es-
tablishing the disease (initiation phase), it is the 
self-perpetuating processes of calcification that 
are predominantly responsible for driving disease 
progression (propagation phase). Despite the ear-
ly enthusiasm that statins may slow the progres-
sion of AS, recent large clinical trials did not con-
sistently demonstrate a decrease in the progres-
sion of AS. However, it is possible that statins may 
have a benefit in early stage of the disease process, 
where inflammation (and not calcification) is the 
predominant process. Positron emission tomogra-
phy using 18F-fluorodeoxyglucose and 18F-sodium 
fluoride can visualize the relative contributions 
of valvular calcification and inflammation in AS, 
and thus this attractive method might be useful 
in providing the answer as to whether pharmaco- 
therapeutic interventions at the earlier stages of 
AS would be more effective in slowing the pro-
gression of the disease.
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accumulation of calcium in the valve leaflets. This 
may explain the failure of statins to modify AS 
progression, which commonly presents beyond 
the initiation phase (SALTIRE,8 ASTRONOMER,9 
and SEAS10 studies). Statin therapy did not mod-
ify progression in moderate to severe AS, but in 
early stage (aortic sclerosis or mild AS), statins 
reduced the plasma level of biomarkers of calcifi-
cation and ossification.11 It is important because 
AS is a pathological process with similarities to 
skeletal bone formation.5
As our understanding of the pathophysiology 
of AS has improved, the key role that calcifica-
tion plays in driving disease progression has led 
us away from targeting inflammation and lipid 
deposition and toward pharmacotherapies capa-
ble of directly preventing valve calcification. The 
close association between disorders of skeletal 
bone metabolism and increased calcification in 
the vasculature offers a potential starting point. 
A growing body of preclinical and clinical find-
ings indicates that treatments for osteoporosis, 
such as bisphosphonates and denosumab, can re-
duce vascular calcification and that these agents 
hold considerable promise as protective pharma-
cotherapies for AS.
Bisphosphonates (widely used for the treat-
ment of osteoporosis) are inhibitors of osteoclast- 
-mediated bone resorption. Importantly, bisphos-
phonates also have cardiovascular effects, dem-
onstrating a consistent reduction in calcification 
both of the vasculature and the aortic valve. They 
reduce the production of interleukin (IL) 1β, IL-
6, and tumor necrosis factor α (key inflamma-
tory cytokines implicated in the early stages of 
AS) and inhibit the secretion of matrix metal-
loproteinases 2 and 9, which remodel the valve 
as AS progresses. Moreover, nitrogen-contain-
ing bisphosphonates operate as inorganic pyro-
phosphate analogs, which have significant anti-
calcific properties in the vasculature. Additional-
ly, bisphosphonates attenuate the differentiation 
of aortic valve myofibroblasts into cells with an 
osteogenic phenotype, the key step in triggering 
the propagation phase of AS. A recent study12 in-
dicated that bisphosphonate treatment was asso-
ciated with less valvular and vascular calcification 
in older women. Other studies appear to support 
these findings with a beneficial effect of bisphos-
phonates on echocardiographic measures of AS 
progression.13-15 The true independent effect of 
bisphosphonates in AS will only be proven after 
a randomized controlled trial.
As concerns the other mechanisms, the OPG/
RANK/RANKL system appears to play a pivotal 
role in aortic valve calcification and may provide 
an explanation for the link between osteoporosis 
and increased vascular calcification. Therefore, it 
represents an attractive therapeutic target for re-
ducing vascular/valvular calcification. Denosumab 
is a human monoclonal antibody to RANKL that 
prevents its binding to RANK. In a murine mod-
el of osteoporosis, denosumab has effectively re-
duced aortic calcification.16
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